Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.83 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.83 |
| ▸ | NPC1 | O15118 | 4/20 | 0.83 |
| ▸ | RAB9A | P51151 | 4/20 | 0.83 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.83 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.74 |
| ▸ | EPAS1 | Q99814 | 3/20 | 0.74 |
| ▸ | LMNA | P02545 | 2/20 | 0.74 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.74 |
| ▸ | HTT | P42858 | 1/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.69 |
| ▸ | MAPT | P10636 | 1/20 | 0.68 |
| ▸ | MITF | O75030 | 1/20 | 0.66 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.66 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.66 |
| ▸ | RELA | Q04206 | 1/20 | 0.66 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.66 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.66 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2956553 | 0.88 | HIF1A (0.93) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL12171985 | 0.87 | HIF1A (0.85) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL20620008 | 0.86 | KMT2A (0.70) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2947496 | 0.86 | MEN1 (0.79) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL12887716 | 0.85 | HIF1A (1.00) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2957651 | 0.85 | MAPT (0.68) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2953609 | 0.84 | NPC1 (0.67) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2959279 | 0.84 | HIF1A (0.82) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2956613 | 0.83 | NPC1 (0.80) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6319696 | 0.83 | HTT (1.00) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060167263-A1 | Acetylamino benzoic acid compounds and their use for nonsense suppression and the treatment of disease | PTC THERAPEUTICS, INC. | 2006-07-27 | — | — | US | claimed |
| EP-1525185-A1 | ACETYLAMINO BENZOIC ACID COMPOUNDS AND THEIR USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASE | PTC Therapeutics, Inc. (US) | 2005-04-27 | — | — | EP | claimed |
| WO-2004009533-A1 | ACETYLAMINO BENZOIC ACID COMPOUNDS AND THEIR USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASE | PTC THERAPEUTICS, INC. (US) | 2004-01-29 | — | — | WO | claimed |
| US-20160199357-A1 | METHODS FOR THE PRODUCTION OF FUNCTIONAL PROTEIN FROM DNA HAVING A NONSENSE MUTATION AND THE TREATMENT OF DISORDERS ASSOCIATED THEREWITH | PTC THERAPEUTICS, INC. | 2016-07-14 | — | — | US | disclosed |
| US-9289398-B2 | Methods for the production of functional protein from DNA having a nonsense mutation and the treatment of disorders associated therewith | PTC THERAPEUTICS, INC. (US) | 2016-03-22 | — | — | US | disclosed |
| EP-2387995-A1 | Methods for the production of functional protein from DNA having a nonsense mutation and the treatment of disorders associated therewith | PTC Therapeutics, Inc. (US) | 2011-11-23 | — | — | EP | disclosed |
| US-20110046136-A1 | METHODS FOR THE PRODUCTION OF FUNCTIONAL PROTEIN FROM DNA HAVING A NONSENSE MUTATION AND THE TREATMENT OF DISORDERS ASSOCICATED THEREWITH | THERAPEUTICS, INC. (US) | 2011-02-24 | — | — | US | disclosed |
| US-7763656-B2 | Use of Acetylamino benzoic acid compounds for nonsense suppression and the treatment of disease | PTC THERAPEUTICS, INC. (US) | 2010-07-27 | — | — | US | disclosed |
| US-7763656-B2 | Use of Acetylamino benzoic acid compounds for nonsense suppression and the treatment of disease | PTC THERAPEUTICS, INC. (US) | 2010-07-27 | — | — | US | disclosed |
| US-7763656-B2 | Use of Acetylamino benzoic acid compounds for nonsense suppression and the treatment of disease | PTC THERAPEUTICS, INC. (US) | 2010-07-27 | — | — | US | disclosed |
| WO-2007117438-A2 | METHODS FOR THE PRODUCTION OF FUNCTIONAL PROTEIN FROM DNA HAVING A NONSENSE MUTATION AND THE TREATMENT OF DISORDERS ASSOCIATED THEREWITH | PTC THERAPEUTICS, INC. (US) | 2007-10-18 | — | — | WO | disclosed |
| US-20070203123-A1 | Use of acetylamino benzoic acid compounds for nonsense suppression and the treatment of disease | PTC THERAPEUTICS, INC. | 2007-08-30 | — | — | US | disclosed |
| US-20070203123-A1 | Use of acetylamino benzoic acid compounds for nonsense suppression and the treatment of disease | PTC THERAPEUTICS, INC. | 2007-08-30 | — | — | US | disclosed |
| US-20070203123-A1 | Use of acetylamino benzoic acid compounds for nonsense suppression and the treatment of disease | PTC THERAPEUTICS, INC. | 2007-08-30 | — | — | US | disclosed |
| US-7247741-B2 | Acetylamino benzoic acid compounds and their use for nonsense suppression and the treatment of disease | PTC THERAPEUTICS, INC. (US) | 2007-07-24 | — | — | US | disclosed |
| US-7247741-B2 | Acetylamino benzoic acid compounds and their use for nonsense suppression and the treatment of disease | PTC THERAPEUTICS, INC. (US) | 2007-07-24 | — | — | US | disclosed |
| US-7247741-B2 | Acetylamino benzoic acid compounds and their use for nonsense suppression and the treatment of disease | PTC THERAPEUTICS, INC. (US) | 2007-07-24 | — | — | US | disclosed |
| US-20060167263-A1 | Acetylamino benzoic acid compounds and their use for nonsense suppression and the treatment of disease | PTC THERAPEUTICS, INC. | 2006-07-27 | — | — | US | disclosed |
| EP-1525185-A1 | ACETYLAMINO BENZOIC ACID COMPOUNDS AND THEIR USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASE | PTC Therapeutics, Inc. (US) | 2005-04-27 | — | — | EP | disclosed |
| WO-2004009533-A1 | ACETYLAMINO BENZOIC ACID COMPOUNDS AND THEIR USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASE | PTC THERAPEUTICS, INC. (US) | 2004-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046136-A1 | METHODS FOR THE PRODUCTION OF FUNCTIONAL PROTEIN FROM DNA HAVING A NONSENSE MUTATION AND THE TREATMENT OF DISORDERS ASSOCICATED THEREWITH | UPF1, DNAJC10, RNGTT | MEN1 3100/4885KMT2A 2713/4885NPC1 2442/4885 |
| US-20160199357-A1 | METHODS FOR THE PRODUCTION OF FUNCTIONAL PROTEIN FROM DNA HAVING A NONSENSE MUTATION AND THE TREATMENT OF DISORDERS ASSOCIATED THEREWITH | UPF1, DNAJC10, RNGTT | MEN1 2786/4885KMT2A 2626/4885NPC1 2269/4885 |
| US-20060167263-A1 | Acetylamino benzoic acid compounds and their use for nonsense suppression and the treatment of disease | UPF1, NAT10, PABPC1 | MEN1 3996/4885KMT2A 2108/4885NPC1 1202/4885 |
| US-20070203123-A1 | Use of acetylamino benzoic acid compounds for nonsense suppression and the treatment of disease | UPF1, NAT10, PABPC1 | MEN1 3772/4885KMT2A 1950/4885NPC1 1463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.